Writing the Specifications for NHIRD Research. Tzeng-Ji Chen
|
|
- Bryan Harrison
- 5 years ago
- Views:
Transcription
1 Writing the Specifications for NHIRD Research Tzeng-Ji Chen
2 From Internet * including 答應來演講?!
3 My Sweet Home
4 3 Months after Furnishing Lesson: Specs do matter.
5 From Internet
6 Key Concepts
7 Paper Production Flow Atmosphere Idea Method Writing Journal Materials Computing Statistics English Teams Tools Infrastructure
8 1. 資料擷取 2. 資料處理 3. 統計分析 Courtesy of Yu-Chun Chen
9 PR time ( )
10 PR time ( )
11 GDP (Good Data Processing) Protocol Diary Script comments Avoid fancy or illegible writing Programming style
12
13
14 File Structure of NHIRD Datasets to Process Single file Multiple files: Of the same format Of similar formats in different years Of different formats, but connected through Primary key / foreign key Loop-up table
15 15
16
17
18 Main Frame of Processing
19 Setting the Goal Quantity One is enough More papers, more better Quality trade-off Fulfilling the minimum requirement High-impact Willingness to pay (for NHIRD datasets) Willingness to devote (time and effort)
20 Writing the Specs for NHIRD Research Decide on the selection of datasets Complete datasets Datasets sampled by visit (OPD + ER: 1/500; Adm.: 1/20) Datasets sampled by person (1 million cohort: old vs. new) Time frame Connected and ancillary datasets Decide on the selection of fields Decide on the processing of fields Define the major events Elaborate the processing workflow interactive, reiterative, collaborative process Decide on the structure and format of output table(s)
21 Real-Life Examples
22 1. Trazodone as poor men's Viagra: a prescription database analysis among urological practice in Taiwan
23 Source of Idea:
24 J Urol 2003;169:
25 J Urol 2003;169:
26 J Urol 2003;169:
27 Datasets (1/3) Ambulatory sector Datasets sampled by visit (=> utilization amount)? Datasets sampled by person (=> prevalence)? Complete datasets (=> $$$) X
28 Datasets (2/3) CD: ambulatory care expenditures by visits (visit file): , OO: details of ambulatory care orders (order file): ,
29 DRUG 藥品主檔 29
30 Datasets (3/3) HOSB: registry for contracted medical facilities? PER: registry for medical personnel? DOC: registry for board-certified specialists? DRUG: registry for drug prescriptions? ID: registry for beneficiaries => + Complete!
31 Fields OO DRUG_NO CD ID, ID_BIRTHDAY, ID_SEX ACODE_ICD9_1, ACODE_ICD9_2, ACODE_ICD9_3 FUNC_DATE FUNC_TYPE, PRSN_ID, HOSP_ID HOSB HOSP_CONT_TYPE, AREA_NO_H ID ID, INS_ID, INS_ID_TYPE, INS_AMT, ID_IN_DATE, ID_OUT_DATE
32 Field Processing Patient s age and age group Age = (FUNC_DATE - ID_BIRTHDAY) in Y? Age = FUNC_DATE in Y - ID_BIRTHDAY in Y? <=39, 40-59, >=60? Diagnosis group Major Dx field? All 3 Dx fields? All Dx groups? ICD-9-CM s first 3 digits CCS single level Target Dx group(s)? (y/n) Visit-based? Person-based? Exclusivity? Non-exclusivity? Hierarchy?
33 Major Event (DRUG_NO) Trazodone (ATC: N06AX05) A A A A A A A A A A A B B B A
34 Data Processing (1/5) Extract records from OO according to DRUG_NO (=> OO_Trazodone_?.txt) Extract records from CD according to PK (FEE_YM + APPL_TYPE + HOSP_ID + APPL_DATE + CASE_TYPE + SEQ_NO) in OO (=> CD_Trazodone_?.txt) Extract records from CD_Trazodone_?.txt according to FUNC_TYPE = 08 (=> CD_Trazodone_?_GU.txt) Extract records from OO_Trazodone_?.txt according to PK in CD_Trazodone_?_GU.txt (=> OO_Trazodone_?_GU.txt) For both S_{CD,OO}{ } and LHID2000 s R{01..20}_{CD,OO}{ } Further processing
35 Trazodone Rx in S_{CD,OO} (1:500) Year No. of Visits with Trazodone No. of GU Visits with Trazodone F + M + U F M F + M + U F M , , , , , , ,164 1,095 1, ,087 1, ,181 1,160 1, ,305 1,265 1, ,358 1,338 1,
36 Data Processing (2/5) For LHID2000 : limited to male patients User in each year Based on FUNC_DATE New user in each year No GU visit with Trazodone Rx in any of previous years Denominator in each year Based on R{01..20}_ID{ } Judged according to ID_IN_DATE and ID_OUT_DATE : ( ID_IN_DATE <= target year ) AND ( ( ID_OUT_DATE = blank ) OR ( ID_OUT_DATE >= target year ) )
37 Trazodone Rx at GU Visits in LHID2000 Year No. of Pat. / No. of New Pat. No. of Male Beneficiaries 0-39 y y 60+ y 0-39 y y 60+ y / / / ,737 99,731 55, / / / , ,946 57, / / / , ,035 58, / / / , ,633 59, / / / , ,791 60, / / / , ,365 61, / / / , ,445 62, / / / , ,940 62, / / / , ,354 63, / / / , ,346 64, / / / , ,060 65, / / / , ,526 66,935
38 Data Processing (3/5) No. of GU visits with Trazodone Rx by a patient between 1997 and 2008 Frequency distribution stratified by patient s age Age : age at the first visit
39
40 Data Processing (4/5) Distribution of diagnoses among GU visits with Trazodone by visit by patient Diagnosis groups (after observing the preliminary Dx distrib.) Impotence : Impotence of organic origin : Psychosexual dysfunction : Unspecified psychosexual disorder Depression 296 : Affective psychoses 300 : Neurotic disorders 311 : Depressive disorder, not elsewhere classified Impotence + Depression
41 impotence depression Visit-based (n = 18,052) 9,002 (49.9%) 1,141 (6.3%) 986 (5.5%) 6,923 (38.4%) impotence depression Pat.-based (n = 4,676) 2,596 (55.5%) 407 (8.7%) 242 (5.2%) 1,431 (30.6%)
42 Data Processing (5/5) Distribution of highest monthly insured income ( insured payroll-related amount ) in patients having GU visits for Trazodone in general population (cohort) excluding patients with Trazodone at GU Highest monthly insured income of a patient between 1997 and 2008 INS_AMT : monthly insured income of type 1-3 of the insured Cave : INS_ID_TYPE = 4 OR 5 after 2006 In an ID record of those insured dependently Income = INS_IDs highest monthly insured income * One can have several INS_IDs. Minimal monthly insured income : arbitrarily set to 14,400
43 Median (IQR) : 33,300 (27,200) (n = 4,676) Median (IQR) : 31,800 (24,800) (n = 499,798) * Wilcoxon rank sum test with continuity correction : p =
44 2. Venous thromboembolism (VTE) among cancer patients in Taiwan
45 Datasets Datasets on special request All claims belonging to cancer patients according to HV registry datasets, > 100 GB ID registry Whole population 43 datasets, 22.6 GB
46 Cancer Patients Patients hospitalized with cancer diagnosis ( ) from (DD) (follow up until 2006) Excluding those who had cancer diagnosis in 1996, either at OPD or at hospitalization
47 VTE Events Hospitalization with VTE diagnosis Pulmonary embolism: DVT: Use of anticoagulants during the hospitalization with VTE diagnosis B01AA: Vitamin K antagonists B01AB: Heparin group (total dose >= 5 KIU / Adm.) VTE Dx AND ( (B01AA [Y]) OR (B01AB [dosage]) )
48 Output Table (1/6) One cancer patient one record 1. ID 2. Date of first cancer diagnosis The IN_DATE of the first hospitalization with cancer diagnosis 3. Birthday 4. Sex
49 Output Table (2/6) 5. Type of first cancer (2 fields) Use original ICD9CM code for cancer Concomitant cancer ICD code => Do not record Type of other cancers than first cancer (judged according to first 3 digits) (5 pairs [dx + IN_DATE]) (in hospitalization records) (only from the records with discharge) (after the time of first cancer diagnosis : IN_DATE of the record > OUT_DATE of first cancer diagnosis)
50 Output Table (3/6) 7. Co-morbidities (in both ambulatory and hospitalization records) (before or at the time of first cancer diagnosis) (consider all existing diagnoses except CM10) CM1: Hypertension ( ): 1 or 0 CM2: DM (250): 1 or 0 CM3: Congestive heart failure (428): 1 or 0 CM4: Ischemic heart disease ( ): 1 or 0 CM5: Renal diseases ( ): 1 or 0 CM6: Liver diseases ( ): 1 or 0
51 Output Table (4/6) 7. Co-morbidities (in both ambulatory and hospitalization records) (before or at the time of first cancer diagnosis) (consider all appearing diagnoses except CM10) CM7: Cerebrovascular disease ( ): 1 or 0 CM8: COPD ( ): 1 or 0 CM9: Hyperlipidemia (272): 1 or 0 CM10: History of VTE (415.1, , before the index hospitalization with cancer diagnosis): 1 or 0 (in hospitalization records) (before the time of first cancer diagnosis)
52 Output Table (5/6) 8. Type of the first VTE event (in hospitalization records) (after or at the time of first cancer diagnosis) No VTE: 0 PE (415.1): 1 DVT ( ): 2 PE + DVT ( ): 3 9. Date of the first VTE event The IN_DATE of the index hospitalization with VTE diagnosis and treatment No VTE: blank
53 Output Table (6/6) 10. Type of death No death / unknown: 0 In-hospital death: 1 Assumed death: 2 (drop-out from NHI within 30 days after the last hospitalization with AAD) 11. Date of last follow-up (OPD or hospitalization or drop-out from NHI) (in living patients), in-hospital death or assumed death
54 Data Processing (1/5) Cancer.plx => Cancer.txt [ PatID, InDate, OutDate, Birthday, Sex, Dx1, Dx2 ] the first admission with cancer diagnosis admission date between 1997 and 2005 because of cancer as one of diagnoses ( ) no cancer diagnosis in 1996, either at OPD or at hospitalizations
55 Data Processing (2/5) VTE_All.plx => VTE_All_DD_ txt, VTE_All_DD_ txt, VTE_All_DO_ txt all admissions with VTE diagnosis not limited to defined cancer patients
56 Data Processing (3/5) VTE.plx => VTE.txt [ PatID, VTEInDate, VTEType ] all admissions with VTE and drug treatment non-heparin (NON_HEPARIN.txt) => VTE heparin (HEPARIN_KIU.txt [ heparin, dosage in KIU ]) dosage >= 5 KIU => VTE not limited to defined cancer patients VTE type : 0 (no), 1 (PE, 415.1), 2 (DVT, ), 3 (PE + DVT)
57 Data Processing (4/5) Death.plx => Death.txt [ PatID, DeathType, LastFUDate ] not limited to defined cancer patients death type : 0 (no), 1 (in-hospital death), 2 (assumed death)
58 Data Processing (5/5) Final.plx (combine Cancer.txt, VTE.txt, Death.txt) => Final.txt [ PatID, InDate, Birthday, Sex, Dx1, Dx2, ExtraCa1, ExtraDate1, ExtraCa2, ExtraDate2, ExtraCa3, ExtraDate3, ExtraCa4, ExtraDate4, ExtraCa5, ExtraDate5, CM1, CM2, CM3, CM4, CM5, CM6, CM7, CM8, CM9, CM10, VTEType, VTEInDate, DeathType, LastFUDate ]
59 Tips in Data Processing (1/2) VTE.txt [ PatID, VTEInDate, VTEType ] B01AA + B01AB : 48 available drug items + 28 old items Heparin s total dosage in a combined full admission (fragmented claims) : based on ID + IN_DATE In all admissions with VTE Dx (not limited to defined cancer patients) with non-heparin : 15,299 admission records with heparin >= 5 KIU / admission record : 8,191 admission records with heparin >= 10 KIU / admission record : 6,988 admission records with heparin >= 25 KIU / admission record : 6,394 admission records with non-heparin or heparin : 18,532 admission records with non-heparin or heparin >= 5 KIU / admission record : 18,120 admission records with non-heparin or heparin >= 10 KIU / admission record : 17,576 admission records with non-heparin or heparin >= 25 KIU / admission record : 17,364 admission records
60 Tips in Data Processing (2/2) Death.txt [ PatID, DeathType, LastFUDate ] Last date of medical care use Last date of hospitalizations (OUT_DATE of the last hospitalization) Last date of ambulatory visits (FUNC_DATE of the last visit) Last date of hospitalization with AAD (discharge against [medical] advice) Last date of entry into insurance Last date of cancellation of insurance ID (?) (=> => ) Patients with in-hospital death : Last date of hospitalization AAD with assumed death : cancellation of insurance within 30 days after the last date of hospitalizations with AAD, and no more entry into insurance Others (living or death unknown) : last date of medical care use as LastFUDate
61 Output 497,185 records into Microsoft Access
62 I have a dream
63 The NHIRD research will enable the current generation of medical professionals in Taiwan to know the Amis better than the Amish. * Amis : 阿美族
64 NHIRD (GPRD) (NAMCS)
65 Cum. no. of papers Courtesy of Yu-Chun Chen Year
66 Thanks for Your Attention!
Symptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study
IMPROVING PATIENT SAFETY Preventing & Managing Venous Thromboembolism Session 8 Data Driving Strategies for VTE Prevention and Management 3/30/2012; 15.35-15.55 Symptomatic Venous Thromboembolism after
More informationWind, Water, Wound, Walk Do the Data Deliver the Dictum?
Wind, Water, Wound, Walk Do the Data Deliver the Dictum? Elizabeth M. Sonnenberg, MD, Caroline E. Reinke, MD MSHP, Edmund K. Bartlett, MD, Karole T. Collier, Giorgos C. Karakousis, MD, Daniel N. Holena,
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Mortality Measures Set
More informationEfficiency Methodology
Efficiency Methodology David C. Schutt, MD Bob Kelley Thomson Healthcare October 2007 Overview Definition Clinical Grouping Methods Implementation Considerations Reporting to Physician Organizations Example
More informationAdrenal Insufficiency in the Elderly: A Nationwide Study of Hospitalizations in Taiwan
Tohoku J. Exp. Med., 2010, 221, 281-285 Adrenal Insufficiency in the Elderly 281 Adrenal Insufficiency in the Elderly: A Nationwide Study of Hospitalizations in Taiwan Yi-Chun Chen, 1 Yu-Chun Chen, 2 Li-Fang
More information全民健康保險研究資料庫在急診醫療利用分析之應用
全民健康保險研究資料庫開發與應用研討會 全民健康保險研究資料庫在急診醫療利用分析之應用 翁瑞宏 嘉南藥理科技大學醫管系暨碩士班助理教授 黃金安 台中榮民總醫院急診醫學科主任 2009 年 9 月 3 日 Outline Jin-An Huang, Rhay-Hung Weng, Wen-Chen Tsai, Wei-Hsiung Hu and Dar-Yu Yang, Analysis of Emergency
More informationMalignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study
Accepted: 9 March 2017 DOI: 10.1111/jop.12570 ORIGINAL ARTICLE Malignant transformation of oral submucous fibrosis in Taiwan: A nationwide population-based retrospective cohort study Po-Yu Yang 1,2 Yi-Tzu
More informationCOST-EFFECTIVENESS ANALYSIS OF ORAL CAVITY CANCER IN TAIWAN: A POPULATION-BASED STUDY
COST-EFFECTIVENESS ANALYSIS OF ORAL CAVITY CANCER IN TAIWAN: A POPULATION-BASED STUDY Hsiang-Tsai Chiang Chun-Yi Tu Lie-Fen Lin Ph.D. Program of Business, Ph.D. Program of Business, Ph.D. Program of Business,
More informationChapter 3: Morbidity and Mortality in Patients with CKD
Chapter 3: Morbidity and Mortality in Patients with CKD In this 2017 Annual Data Report (ADR) we introduce analysis of a new dataset. To provide a more comprehensive examination of morbidity patterns,
More informationJAWDA Performance Quarterly KPI Profile (Clinic & Centers) March 2018
JAWDA Performance KPI Profile (Clinic & Centers) March 2018 1 P a g e Introduction: Physician office, clinic, and healthcare centers provide primary care function including health education, prevention,
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationClinical Safety & Effectiveness Session # 9
Clinical Safety & Effectiveness Session # 9 Women s Health Venous Thromboembolism Prophylaxis DATE Educating for Quality Improvement & Patient Safety 1 What We Are Trying to Accomplish? OUR AIM STATEMENT
More informationASSESSMENT OF EFFECTIVENESS
W.M. Glinkowski 1,2,3,A.Górecki 1 WEB BASED DATABASE FOR THE ASSESSMENT OF EFFECTIVENESS OF THROMBOEMBOLIC PROPHYLAXIS IN ORTHOPAEDIC SURGERY. PRELIMINARY STUDY 1 Chair and Department of Orthopaedics and
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationSOC s Guide to the 2013 CMS New Core Measures for Stroke
SOC s Guide to the 2013 CMS New Core Measures for Stroke Since 2004, the Centers for Medicare & Medicaid Services (CMS) has collected quality data from acute care hospitals on a voluntary basis under the
More informationResearch Article Patterns of Nonemergent Visits to Different Healthcare Facilities on the Same Day: A Nationwide Analysis in Taiwan
e Scientific World Journal, Article ID 627580, 8 pages http://dx.doi.org/10.1155/2014/627580 Research Article Patterns of Nonemergent Visits to Different Healthcare Facilities on the Same Day: A Nationwide
More informationSCORES FOR 4 TH QUARTER, RD QUARTER, 2014
SCORES FOR 4 TH QUARTER, 2013 3 RD QUARTER, 2014 PATIENT SATISFACTION SCORES (HCAHPS): 4 STARS OUT OF 5 (ONLY 4 AREA ACUTE CARE HOSPITALS RECEIVED A 4-STAR RATING. NONE ACHIEVED 5-STARS). STRUCTURAL MEASURES:
More information50198 Federal Register / Vol. 75, No. 157 / Monday, August 16, 2010 / Rules and Regulations
50198 Federal Register / Vol. 75, No. 157 / Monday, August 16, 2010 / Rules and Regulations mstockstill on DSKH9S0YB1PROD with RULES2 VerDate Mar2010 17:02 Aug 13, 2010 Jkt 220001 PO 00000 Frm 00158
More informationRegistry Highlights. Dale Daniel Symposium Hip Fracture Registry. Overall Volume by Year and Region 3/7/2014
Dale Daniel Symposium 2014 Registry Highlights Overview: Updated Volume NCAL/SCAL Snapshot Hip Fracture Registry Update Gary Zohman, MD SCAL Regional Lead Anaheim, CA Quarterly Quality Report Review Future
More informationZhao Y Y et al. Ann Intern Med 2012;156:
Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled
More informationAdjunct Lecturer. National Yang-Ming University, Taiwan. Taipei Veterans General Hospital, Taiwan
Kuan-Po Peng MD Adjunct Lecturer National Yang-Ming University, Taiwan Taipei Veterans General Hospital, Taiwan Nothing to declare Disclosure Experience from the Taiwan National Health Insurance Research
More informationDetermining differences in health care costs before and after Alzheimer s diagnosis using SAS Studio
Determining differences in health care costs before and after Alzheimer s diagnosis using SAS Studio ABSTRACT Problem: Delayed or missed diagnoses of Alzheimer s might deprive afflicted individuals of
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationComprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma
Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca
More informationClinical Trend Discovery and Analysis of Taiwanese Health Insurance Claims Data. Divya P. Pillai. S.B., Massachusetts Institute of Technology (2015)
Clinical Trend Discovery and Analysis of Taiwanese Health Insurance Claims Data by Divya P. Pillai S.B., Massachusetts Institute of Technology (2015) Submitted to the Department of Electrical Engineering
More informationBoehringer Ingelheim Page 6 of 178 Study report for non-interventional studies based on existing data BI Study Number
Page 6 of 178 report for non-interventional studies based on existing data BI Number 1160.144 c14462719-01 International GmbH or one or more of its affiliated companies 1. ABSTRACT Title of study: Keywords:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationDefinitions of chronic conditions used to define the number of serious comorbidities in the study.
Supplementary Table 1 Definitions of chronic conditions used to define the number of serious comorbidities in the study. Comorbidity ICD-9 Code Description CAD/MI 410.x Acute myocardial infarction 411.x
More informationTable 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings
CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience
More informationAn Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH
An Analysis of Prescribing of Methylphenidate Hydrochloride in QRESEARCH An analysis using QRESEARCH for the Department of Health Authors: Professor Julia Hippisley-Cox Professor Mike Pringle Ronan Ryan
More informationSite Training. The 39 th Multicenter Airway Research Collaboration (MARC-39) Study
Site Training The 39 th Multicenter Airway Research Collaboration (MARC-39) Study 1 Study Leadership Kohei Hasegawa, MD, MPH (PI) Carlos Camargo, MD, DrPH (Co-I) Project Coordination: Catalina Gimenez-Zapiola
More informationUnstable INR Has Implications for Healthcare Resource Use. Janssen Pharmaceuticals, Inc.
Unstable INR Has Implications for Healthcare Resource Use Janssen Pharmaceuticals, Inc. Stable INR is essential for effective anticoagulation treatment Achieving a stable international normalized ratio
More informationDrug prescriptions (Pharm) Exposure (36/48 months)
ANNEX SECTION PART A - Study design: Figure 1 overview of the study design Drug prescriptions (Pharm) 2006-2010 Exposure (36/48 months) flexible time windows (e.g. 90 days) time index date (hospital discharge)
More informationPHARMO Database Network
Pros & cons in Oncology studies PHARMO Myrthe Database van Herk-Sukel, Network PhD 1 Disclosure Myrthe van Herk-Sukel is an employee of the PHARMO Institute for Drug Outcomes Research. This independent
More informationEHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee. Study Background
EHMRG SCORE STUDY version 6.2; date: 11Jul11 PI: Dr. Douglas Lee Study Background Heart failure (HF) is a leading cause of morbidity and cardiovascular mortality. The burden of HF has increased over time
More informationPHPG. Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions
PHPG The Pacific Health Policy Group Utilization and Expenditure Analysis for Dually Eligible SoonerCare Members with Chronic Conditions Prepared for: State of Oklahoma Oklahoma Health Care Authority April
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationACO/HCC/Coding Presentation
ACO/HCC/Coding Presentation Prepared by Kristin & Sheree Date 5/15/2013 CMP ACO Background CMP is participating in the Medicare Shared Savings ACO program (Track 1) which is a 3 year agreement With Track
More informationCommercial Health Insurance Claims Data. for Studying HIV/AIDS Care. Senior Scientist, Innovus Epidemiology. David D.
Commercial Health Insurance Claims Data for Studying HIV/AIDS Care David D. Dore, PharmD, PhD Senior Scientist, Innovus Epidemiology Adjunct Assistant Professor, Alpert Medical School, Brown University
More informationSurgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018
Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report May 2018 Prepared by the Canadian Cardiovascular Society (CCS)/Canadian Society of Cardiac Surgeons (CSCS) Cardiac
More informationA guide to anticoagulation management and self-testing
A guide to management and self-testing Understanding If you re reading this, you, or someone you care about, may be on oral therapy, usually treated with a vitamin K antagonist (VKA). VKAs, such as warfarin,
More informationWarfarin & You By V. B. Blake
Warfarin & You By V. B. Blake Warfarin is an anticoagulant used to to prevent heart attacks, strokes, and blood clots. Learn about side effects, interactions and indications. Can you tell me what I should
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationTrends in Pneumonia and Influenza Morbidity and Mortality
Trends in Pneumonia and Influenza Morbidity and Mortality American Lung Association Epidemiology and Statistics Unit Research and Health Education Division November 2015 Page intentionally left blank Introduction
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Clinical and economic effectiveness of an inpatient anticoagulation service Mamdani M M, Racine E, McCreadie S, Zimmerman C, O'Sullivan T L, Jensen G, Ragatzki P, Stevenson J G Record Status This is a
More informationDisease Management. Measures At A Glance
s At A Glance Updated: 11/01/2018 URAC 2018 Page 1 of 7 Cross-Cutting Mandatory s (3) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on
More informationTrends in Hospice Utilization
Proposed FY 2017 Hospice Wage Index and Rate Update and Hospice Quality Reporting Requirements To: NHPCO Provider Members From: Health Policy Team Date: April 25, 2016 On April 21, 2016, the Centers for
More informationAppendix G Explanation/Clarification Summary
Appendix G Explanation/Clarification Summary Summary of Changes for Recommendations Alignment of measures with VBP by fiscal year Measures and service dates were adjusted to be consistent with the FY2016
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationSupplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
More information2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement
2016 Physician Quality Reporting System Data Collection Form: Total Knee Replacement IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory reporting.
More informationIs laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass?
Is laparoscopic sleeve gastrectomy safer than laparoscopic gastric bypass? A comparison of 30-day complications using the MBSAQIP data registry Sandhya B. Kumar MD, Barbara C. Hamilton MD, Soren Jonzzon,
More informationAppendix 1 (as supplied by the authors): Databases and definitions used.
Appendix 1 (as supplied by the authors): Databases and definitions used. Table e1: The Institute for Clinical Evaluative Sciences databases used in this study and their descriptions Database Ontario Health
More informationSupplementary Online Content
Supplementary Online Content Pincus D, Ravi B, Wasserstein D. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. doi: 10.1001/jama.2017.17606 eappendix
More informationTesting for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness
Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a costeffectiveness analysis Eckman M H, Singh S K, Erban J K, Kao G Record Status This is a critical abstract of an economic
More informationPerformance Analysis:
Performance Analysis: Healthcare Utilization of CCNC- Population 2007-2010 Prepared by Treo Solutions JUNE 2012 Table of Contents SECTION ONE: EXECUTIVE SUMMARY 4-5 SECTION TWO: REPORT DETAILS 6 Inpatient
More informationComparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments
Comparison of Medicare Fee-for-Service Beneficiaries Treated in Ambulatory Surgical Centers and Hospital Outpatient Departments Prepared for: American Hospital Association April 4, 2019 Berna Demiralp,
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set
More informationProposed Expansion of the Patient Safety Indicator Set Patrick S. Romano, MD MPH UC Davis/USA
Proposed Expansion of the Patient Safety Indicator Set Patrick S. Romano, MD MPH UC Davis/USA OECD Health Care Quality Indicators Patient Safety Subgroup 9 May 2012 AHRQ PSIs endorsed by OECD (after review
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationPresenter Disclosure Information
Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES
More informationConnecticut Joint Replacement Institute (CJRI) Outcomes Report
Connecticut Joint Replacement Institute () Outcomes Report Our Highlights: Nationally recognized Over 27,000 surgeries performed Devoted to excellence in patient care Proven superior outcomes that matter.
More informationChapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
More informationEffectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study
Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin Among Patients with Sickle Cell Disease: A Retrospective Cohort Study Megan Roberts, PharmD, BCPS MUSC Medical Center and South Carolina
More informationCLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationDALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO
RIVAROXABAN DALLA REAL LIFE INTERNAZIONALE A QUELLA ITALIANA: ESPERIENZE DAL CAMPO Giuseppe Camporese, MD Azienda Ospedaliera Universitaria di Padova Dipartimento di Scienze Cardiache, Toraciche e Vascolari
More informationObjectives. Medicare Spending per Beneficiary: Analyzing MSPB Data to Identify Primary Drivers
Medicare Spending per Beneficiary: Analyzing MSPB Data to Identify Primary Drivers August 22, 2017 Objectives Understand the basics of the hospital specific MSPB data files and reports Review the factors
More information2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative
2014 Evidence-Based HTN Guideline: Preliminary Data from AMGA s Anceta Collaborative February 2014 Patient Population Measure spec for MU/PD generally follows NQF 0018 (used for HEDIS, PQRS, and MU) 1.6
More information4. Which survey program does your facility use to get your program designated by the state?
TRAUMA SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationMeasure Applications Partnership. Hospital Workgroup In-Person Meeting Follow- Up Call
Measure Applications Partnership Hospital Workgroup In-Person Meeting Follow- Up Call December 21, 2016 Feedback on Current Measure Sets for IQR, HACs, Readmissions, and VBP 2 Previously Identified Crosscutting
More informationStanding Posture at Work Does Not Increase the Risk of Varicose Veins among Health Care Providers in Taiwan
Original Paper Received: July 20, 2016 Accepted: February 28, 2017 Published online: February 28, 2017 Standing Posture at Work Does Not Increase the Risk of Varicose Veins among Health Care Providers
More informationBehavioral Health Hospital and Emergency Department Health Services Utilization
Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationDr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton
Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationBackground. Correlation between epilepsy and attention deficit hyperactivity disorder. Background. Epidemiology of ADHD among children with epilepsy
Correlation between epilepsy and attention deficit hyperactivity disorder I-Ching Chou M.D. Director, Department of Pediatric Neurology China Medical University Hospital Taiwan Background Attention deficit/hyperactivity
More informationPossible Denominator Codes Applicable to OMS * Le Fort Fractures 21346, 21347, 21348, 21422, 21423, 21432, 21433, 21435, 21436
2015 Individual PQRS s Eligible OMS #22: Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non- Cardiac Procedures) Percentage of noncardiac surgical patients aged 18 years and older undergoing
More informationUnderstanding Hierarchical Condition Categories (HCC)
Understanding Hierarchical Condition Categories (HCC) How hierarchical condition category coding will impact your practice and how you can use these codes to increase quality, improve the patient experience,
More informationThe Cost Burden of Worsening Heart Failure in the Medicare Fee For Service Population: An Actuarial Analysis
Client Report Milliman Client Report The Cost Burden of Worsening Heart Failure in the Medicare Fee For Service Population: An Actuarial Analysis Prepared by Kathryn Fitch, RN, MEd Principal and Healthcare
More informationStatus Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationPedCath IMPACT User s Guide
PedCath IMPACT User s Guide Contents Overview... 3 IMPACT Overview... 3 PedCath IMPACT Registry Module... 3 More on Work Flow... 4 Case Complete Checkoff... 4 PedCath Cath Report/IMPACT Shared Data...
More informationTools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes.
Tools to manage the introduction of new drugs in Italy: administrative databases, registries and risk-sharing sharing schemes. Roberta Joppi - Italian Horizon Scanning Project Local Health Unit of Verona
More informationTop Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationWHI Extension Appendix A, Form 33D Medical History Update (Detail) (Ver. 9) Page 1
WHI Extension Appendix A, Form 33D Medical History Update (Detail) (Ver. 9) Page 1 FORM: 33D - MEDICAL HISTORY UPDATE (Detail) Version: 9 March 30, 2007 Description: When used: Self-administered or interviewer-administered;
More informationAn Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population
An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population A Population-Based Case-Control Study Hsin-I Shih, Che-Chen Lin, Yi-Fang Tu, Chia-Ming Chang,
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationPartial Hospitalization Program Program for Evaluating Payment Patterns Electronic Report. User s Guide Sixth Edition. Prepared by
Partial Hospitalization Program Program for Evaluating Payment Patterns Electronic Report User s Guide Sixth Edition Prepared by Partial Hospitalization Program Program for Evaluating Payment Patterns
More informationIs Hospital Admission Useful for Syncope Patients? Preliminary Results of a Multicenter Cohort
Is Hospital Admission Useful for Syncope Patients? Preliminary Results of a Multicenter Cohort F. Dipaola, E. Pivetta, G. Costantino, G. Casazza, M.J. Reed, B. Sun, M. Solbiati, F. Barbic, D. Shiffer,
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationData Fusion: Integrating patientreported survey data and EHR data for health outcomes research
Data Fusion: Integrating patientreported survey data and EHR data for health outcomes research Lulu K. Lee, PhD Director, Health Outcomes Research Our Development Journey Research Goals Data Sources and
More information